VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Herpes simplex virus DNA vaccine encoding gD and gB from HSV-2 strain Curtis rOka-gD2- HSV-2
Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004370
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse, guinea pig
  • Antigen: gD and gB from HSV-2 strain Curtis (McClements et al., 1997)
  • gD gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector V1Jns expressed HSV envelope glycoproteins D (gD) (McClements et al., 1997).
    • Detailed Gene Information: Click Here.
  • UL27 gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector V1Jns expressed HSV envelope glycoprotein B (UL27) (McClements et al., 1997).
    • Detailed Gene Information: Click Here.
  • Vector: V1Jns (McClements et al., 1997)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004710
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • gD gene engineering:
    • Type: Recombinant vector construction
    • Description: The herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome (Heineman et al., 1995).
    • Detailed Gene Information: Click Here.
  • Preparation: Herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome (Heineman et al., 1995).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response

Guinea pig Response

  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Immunization with a plasmid expressing gB induced humoral immune responses and virus neutralization (McClements et al., 1997).
  • Efficacy: When the gB plasmid was combined with a plasmid expressing full-length gD, immunized guinea pigs developed humoral responses to both proteins and were also significantly protected from viral challenge. In addition, immunized animals were partially protected from genital herpes, exhibiting significantly reduced primary and subsequent recurrent disease (McClements et al., 1997).

Guinea pig Response

  • Vaccination Protocol: The guinea pigs were inoculated with three doses of uninfected human fibroblasts, fibroblasts infected with ROka VZV, or fibroblasts infected with ROka-gD2 (Heineman et al., 1995).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The guinea pigs were challenged intravaginally with HSV-2 (Heineman et al., 1995).
  • Efficacy: Inoculation of guinea pigs with ROka-gD2 significantly reduced the severity of primary HSV-2 infection (P < 0.001). These experiments demonstrate that the Oka strain of VZV can be used as a live virus vector to protect animals from disease with a heterologous virus (Heineman et al., 1995).
References References
McClements et al., 1997: McClements WL, Armstrong ME, Keys RD, Liu MA. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs. Vaccine. 1997; 15(8); 857-860. [PubMed: 9234533].
Heineman et al., 1995: Heineman TC, Connelly BL, Bourne N, Stanberry LR, Cohen J. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. Journal of virology. 1995; 69(12); 8109-8113. [PubMed: 7494331].